Development of non‐ABO RBC alloantibodies in patients undergoing allogeneic HPC transplantation. Is ABO incompatibility a predisposing factor?

Rubia, Javier de la; Arriaga, F; Andreu, Rafael; Sanz, Guillermo; Jiménez, Carmen; Vicente, Ana I.; Carpio, Nelly; Marty, M; Sanz, Miguel Á.

doi:10.1046/j.1537-2995.2001.41010106.x

Cited by 40 publications

(19 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients undergoing BMT are at risk for alloimmunization and hemolysis [5,44,45]. Although BMT patients are profoundly immunosuppressed after myeloablation, minor RBC antibodies may occur either as a result of passenger lymphocytes from the graft [44,46], myeloablation-resistant host lymphocytes [5,46], or a primary alloimmune response to RBC transfusion [45,46].…”

Section: Incidence Of Minor Rbc Antigen Alloimmunization In Various Cmentioning

confidence: 99%

“…Although BMT patients are profoundly immunosuppressed after myeloablation, minor RBC antibodies may occur either as a result of passenger lymphocytes from the graft [44,46], myeloablation-resistant host lymphocytes [5,46], or a primary alloimmune response to RBC transfusion [45,46]. In the event of a primary alloimmune response, the source of minor RBC antigens in current practice is most likely RBC transfusions [47].…”

Section: Incidence Of Minor Rbc Antigen Alloimmunization In Various Cmentioning

confidence: 99%

“…This is particularly true in female patients of childbearing potential (due to the risk for hemolytic disease of the fetus and newborn) and for patients that may require extended transfusion support and/or stem cell transplantation [5,44,45,46]. An extensive review of RBC mitigation strategies, both current and experimental, has recently been published [74].…”

Section: Practical Clinical Approaches To Limit Alloimmunization and mentioning

confidence: 99%

See 2 more Smart Citations

The Influence of Clinical and Biological Factors on Transfusion-Associated Non-ABO Antigen Alloimmunization: Responders, Hyper-Responders, and Non-Responders

Gehrie

Tormey

2014

Transfus Med Hemother

View full text Add to dashboard Cite

In the context of transfusion medicine, alloimmunization most often refers to the development of antibodies to non-ABO red blood cell (RBC) antigens following pregnancy, transfusion, or transplantation. The development of RBC alloantibodies can have important clinical consequences, particularly in patients who require chronic transfusions. It has been suggested that alloimmunization is more common in some clinical circumstances and patient populations than in others. As such, individuals that develop alloantibodies are frequently referred to as ‘responders' in the medical literature. In contrast, individuals that do not develop alloantibodies despite repeated exposures to non-self blood group antigens have been referred to as ‘non-responders'. The purpose of this article is to review the phenomenon of RBC alloimmunization in the context of responders and non-responders to: i) establish a basic framework for alloimmunization as reported across several diverse patient populations; ii) more fully explore literature reports which support the concept of responders/non-responders regarding blood group antigen alloimmunization; iii) summarize the mechanisms that have been shown to predispose an individual to alloimmunization to determine how these factors may differentiate ‘responders' from ‘non-responders'; and iv) briefly discuss some practical approaches to prevent alloimmunization in patients who may be prone to alloantibody development.

show abstract

Section: Incidence Of Minor Rbc Antigen Alloimmunization In Various Cmentioning

confidence: 99%

Section: Incidence Of Minor Rbc Antigen Alloimmunization In Various Cmentioning

confidence: 99%

Section: Practical Clinical Approaches To Limit Alloimmunization and mentioning

confidence: 99%

See 1 more Smart Citation

The Influence of Clinical and Biological Factors on Transfusion-Associated Non-ABO Antigen Alloimmunization: Responders, Hyper-Responders, and Non-Responders

Gehrie

Tormey

2014

Transfus Med Hemother

View full text Add to dashboard Cite

show abstract

“…Previous reports describe only occasional instances of Rh D alloimmunization after Rh D-incompatible transplants. 1,2 We recently encountered a case of persistent anti-Rh D alloimmunization following allogeneic hematopoietic SCT, and reviewed our institutional experience for patients undergoing myeloablative conditioning and RIC allogeneic hematopoietic SCT to gain current insight regarding the incidence and potential clinical significance of Rh D alloimmunization in this setting.…”

mentioning

confidence: 99%

Rh D alloimmunization in allogeneic HSCT

Chan

Tokessy

Saidenberg

et al. 2012

Bone Marrow Transplant

View full text Add to dashboard Cite

“…A patient with chronic myeloid leukemia developed a severe immune hemolytic anemia due to multiple RBC alloantibodies several weeks after allogeneic SCT [91]. De la Rubia et al [92] demonstrated an immunization rate of 3.7% for non-ABO RBC antibodies after allogeneic SCT. They observed antibody formation more frequently in ABO-mismatched cases, suggesting a potential role of this incompatibility in facilitating antibody production.…”

Section: Non-abo Blood Group Differences and Antibodiesmentioning

confidence: 99%

Relevance of Blood Group Differences and Antibodies in Allogeneic Stem Cell Transplantation

Cassens¹,

Sibrowski²

2002

Transfus Med Hemother

View full text Add to dashboard Cite

Improved experimental and clinical experiences resulted in continuously increasing numbers of allogeneic stem cell transplantation (SCT) during the past years. Nevertheless, severe immunologic side effects remain major risk factors. It is well known that disparities in major histocompatibility complex (MHC) genes and antigens play a dominant role in the induction of cellular immune responses, clinically manifested as graft versus host diseases (GVHD) or graft failures. In contrast, blood group differences, e.g. ABO incompatibilities, are often not considered as significant risk factors although severe clinical complications have been described after blood group-discrepant allogeneic SCT. Major ABO-incompatible SCT may lead to delayed cell engraftment and pure red cell aplasia. In contrast, minor ABO blood group incompatibilities are caused by administration of donor antibodies or by donor plasma cells leading to a passenger lymphocyte syndrome. Furthermore, several therapeutic methods such as T-cell depletion of stem cell transplants or treatment with cyclosporine without methotrexate are known as risk factors to develop immune hemolysis. Finally, it was recently demonstrated that other red blood cell antibodies such as anti-Kell inhibit the clonogenicity of erythrocyte and megakaryocyte progenitor cells and may therefore influence the engraftment after allogeneic SCT. Therefore, it is desirable for specialists in transfusion medicine to know the relevance of blood group antibodies in allogeneic SCT in order to perform diagnostic and/or therapeutic procedures. This article reflects the main immunologic and clinical risk factors in allogeneic SCT caused by blood group differences and corresponding antibodies.

show abstract

Development of non‐ABO RBC alloantibodies in patients undergoing allogeneic HPC transplantation. Is ABO incompatibility a predisposing factor?

Cited by 40 publications

References 29 publications

The Influence of Clinical and Biological Factors on Transfusion-Associated Non-ABO Antigen Alloimmunization: Responders, Hyper-Responders, and Non-Responders

The Influence of Clinical and Biological Factors on Transfusion-Associated Non-ABO Antigen Alloimmunization: Responders, Hyper-Responders, and Non-Responders

Rh D alloimmunization in allogeneic HSCT

Relevance of Blood Group Differences and Antibodies in Allogeneic Stem Cell Transplantation

Contact Info

Product

Resources

About